Evolus' competitive position has shifted: Jeuveau (prabotulinumtoxinA) is now the company's primary growth driver and margin engine, eclipsing the legacy device business (Evoke RF). The injectable platform—built on Evolus Rewards rebate program and direct-to-practice relationships—is generating the predictable, recurring revenue that investors value in toxin franchises.